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INTRODUCTION
Breast cancer, a common malignancy in women, is increas-
ing in incidence world-wide. In Korea, 57% of breast cancer
patients are younger than 50 yr of age (National Center for
Health Statistics, Korea, 2001-2003), while in the United
States, only 22% of patients are younger than 50 (SEER, 1993-
1997). The survival rates of breast cancer patients have im-
proved owing to earlier detection and more effective treat-
ments (1), resulting in increased concern about the quality
of post-chemotherapy life. Among a variety of long-term
sequelae of chemotherapy, permanent ovarian damage is par-
ticularly important for young breast cancer survivors; this can
result from hypoestrogenic symptoms as well as loss of fertili-
ty. In an effort to address these problems, investigators have
attempted ovarian suppression using a gonadotropin releas-
ing hormone agonist (GnRHa) during adjuvant chemother-
apy. GnRHa has been used to interrupt oocyte maturation
during meiosis to protect the ovary (2). Several trials have
reported higher rates of resumption of spontaneous ovulato-
ry cycles in patients with hematological malignancies who
received both chemotherapy and GnRHa simultaneously than
those who received chemotherapy alone (3, 4). The majority
of these trials enrolled patients with leukemia or Hodgkin’s
disease, thus data regarding patients with breast cancer are
still lacking, especially patients of reproductive age (5, 6). Stud-
ies involving breast cancer patients have typically broadly
enrolled premenopausal patients instead of exclusively repro-
ductive-aged women (<35 yr of age), in addition to using
menstrual patterns as a marker of ovarian function. Current-
ly, large randomized controlled trials are underway to evalu-
ate the efficacy of ovarian suppression in women undergoing
breast cancer treatment, and clinicians worldwide are antic-
ipating the results of these trials. However, in Korea, where
there is a different incidence pattern of breast cancer compared
to Western countries, there have been no studies regarding
the protective effects of GnRHa on ovarian function in pati-
ents of reproductive age with breast cancer. Currently, GnRHa
has been evaluated as a new treatment modality for breast
cancer; one study reported that chemotherapy with GnRHa
improved clinical outcomes. We therefore designed this study
to evaluate ovarian function after GnRHa administration to
young Korean breast cancer patients receiving cytotoxic che-
motherapy. Our study is unique in that 1) the upper age of
patients enrolled was limited to the early 30s (mean age: 30.59
±0.13 yr); 2) ovarian function was serially assessed by serum
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GnRH Agonist Therapy to Protect Ovarian Function in Young Korean
Breast Cancer Patients
The increased survival of patients with breast cancer has given rise to other prob-
lems associated with the complications of chemotherapy. One major complication
is premature ovarian failure, an especially harmful outcome for women of reproduc-
tive age. This study was performed to evaluate the efficacy of GnRH agonist (GnRHa)
treatment on protecting ovarian function in young breast cancer patients (30.59±
5.1 yr) receiving chemotherapy after surgery. Twenty-two women were enrolled and
given subcutaneous injections of leuprolide acetate (3.75 mg) every 4 weeks during
chemotherapy. Follow-up laboratory tests (luteinizing hormone [LH], follicle stimulating
hormone [FSH], and estradiol) were performed 1, 3, and 6 months after chemother-
apy. Menstruation patterns and clinical symptoms were followed up for a mean dura-
tion of 35.6±1.7 months. FSH and LH levels were normal in all patients 6 months
after completing chemotherapy (8.0±5.3, 4.4±2.7 mIU/mL, respectively). During
follow-up, none of the patients complained of menopausal symptoms and 81.8%
experienced recovery of menstruation. This report is the first trial of GnRHa as a
treatment modality to protect ovarian function during adjuvant chemotherapy in
young Korean breast cancer patients. 
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hormone levels as well as menstrual patterns; 3) this is the
first trial on this subject in Korea, where the incidence of
breast cancer is higher in the younger reproductive-age group
than in Western countries.
MATERIALS AND METHODS
We initially recruited 34 women of reproductive age with
adenocarcinoma of the breast. We excluded 10 women whose
serum was not sampled on follow-up, one woman who receiv-
ed fewer than four injections during chemotherapy, and one
woman who refused chemotherapy. The remaining 22 women
completed the study protocol, first receiving primary surgi-
cal therapy, then chemotherapy, and finally radiation therapy
(RT). The field of RT did not include the pelvis. All patients
were younger than 35 yr and had a history of normal ovari-
an function (follicle stimulating hormone [FSH] level <10
mIU/mL, luteinizing hormone [LH] level <10 mIU/mL) and
regular menstrual cycles. The patients had no history of prior
chemotherapy or hormone therapy. The institutional review
board at Samsung Medical Center, Sungkyunkwan Univer-
sity School of Medicine, approved this study protocol. 
Before initiation of chemotherapy, a hormonal profile of
FSH, LH, estradiol, progesterone, prolactin, and TSH levels
was obtained and a subcutaneous injection of leuprolide acetate
(3.75 mg, Leuplin, Takeda Chemical Industries Ltd., Osaka,
Japan) was given. To avoid possible toxic effects of the che-
motherapeutic agents prior to ovarian suppression, chemother-
apy was not started until ovarian suppression was confirmed
by measurement of serum estradiol level (<30 pg/mL), taken
2 weeks after leuprolide acetate treatment. The chemothera-
py regimens were determined by oncologists according to
individual cancer characteristics and patient prognosis and
the patients with estrogen receptor positive tumors were provid-
ed tamoxifen medication from 3 weeks after the completion
of chemotherapy. Thereafter, leuprolide acetate was admin-
istered every 4 weeks until the completion of chemotherapy.
The cut-off values of increased FSH and LH were >20 mIU/
mL for each hormone. In addition, daily calcium supplemen-
tation (1,500 mg/d) was recommended. 
Nine patients received 600 mg/m2 cyclophosphamide and
60 mg/m2 doxorubicin every 3 weeks for four cycles. Seven
patients received 600 mg/m2 cyclophosphamide, 60 mg/m2
doxorubicin, and 175 mg/m2 paclitaxel every 3 weeks for four
cycles. Six patients received 500 mg/m2 cyclophosphamide,
50 mg/m2 doxorubicin, and 500 mg/m2 5-fluorouracil every
3 weeks for six cycles. 
Follow-up laboratory tests to measure LH, FSH, estradiol,
and progesterone were performed 1, 3, and 6 months after
completion of chemotherapy. For statistical analysis, inde-
pendent t-test or Fisher’s exact test, Wilcoxon Signed Ranks
test, and Kruskal-Wallis test with LSD were used. A P value
<0.05 was considered significant. Menstrual patterns and
symptoms of ovarian failure were observed for a mean dura-
tion of 35.6±1.79 months (mean±SD). The patients were
questioned about their menstruation and menopausal symp-
toms (hot flashes, sweating, and vaginal dryness). The tele-
phone interview was performed in those patients who did not
visit the hospital after the last serum sample was collected. 
As a preliminary study, we used GnRHa in all patients
because ethically all patients should receive the potentially
protective treatment. Although the current study had no con-
trol group, the assessment of serial hormonal levels should
reflect the effects of GnRHa treatment. Therefore, instead
of recruiting control patients, our results were compared with
those already described in the medical literature for similar
patients who received chemotherapy without GnRHa. 
RESULTS
Demographic and clinical profiles of breast cancer patients
Patient characteristics are summarized in Table 1. The mean
age at diagnosis was 30.6±5.1 yr, and the mean age of menar-
Parameters Mean±SD or n (%) 
Age at diagnosis (yr) 30.59±0.13*
Age of menarche (yr) 13.50±0.30*
BMI at diagnosis (kg/m
2) 21.00±0.68*
Body surface area (m
2)1 . 5 6 ±0.90*
Previous pregnancy history (+) 1 (4.5)
Breast cancer stage (TNM)
I 8 (36.3)
IIa 4 (18.1)
IIb 6 (27.2)
IIIa 4 (18.1)
Hormone receptor status
ER (+)/PR(+) or PR(-) 15 (68.2) or 2(9.0)
ER(-)/ PR (-) or PR(+) 1 (4.5) or 4(18.2)
Type of primary surgery
BCS 12 (54.5)
MRM 9 (40.9)
TM 1 (4.5)
Chemotherapy regimen
AC 9 (40.9)
AC+Paclitaxel 7 (31.8)
CAF 6 (27.2)
Radiation treatment (RT)
No RT 0 (0)
RT 21 (100)
Tamoxifen medication 17 (77.2)
Table 1. Demographic and clinical profiles of breast cancer
patients
*Data expressed as mean±SD.
BCS, Breast conservative surgery; MRM, Modified radical mastecto-
my; TM, Total mastectomy; AC, doxorubicin, cyclophosphamide; CAF,
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che was 13.5±6.3 yr. All patients had regular menstrual
cycles prior to chemotherapy and 4.5% (1/22) of the patients
had been pregnant previously. Prior to chemotherapy, the mean
body mass index (BMI) was 21.0±0.7 kg/m2 and the mean
body surface area was 1.6±0.9 m2. Eight women had stage
I or II disease and four women had stage III disease. Breast
conservation surgery was performed in 54.5% (12/22) of pati-
ents. Patients with estrogen receptor-positive tumors received
tamoxifen (17/22). All patients received radiation therapy that
excluded the pelvis. 
Chemotherapeutic agents
Nine patients (41%) received four courses of doxorubicin
and cyclophosphamide (AC) with four courses of paclitaxel,
seven patients (31.8%) received four courses of AC only, and
Cyclophosphamide
(mg)
Doxorubicin 
(mg)
Total (n=22) 3706.1±83.6 380.3±11.6
AC (n=9) 3598.6±93.8* 360.7±9.8
AC+Paclitaxel (n=6) 3443.0±117.2* 349.3±86.7
CAF (n=7) 4512.5±103.2* 451.50±12.7
Table 2. Total doses of chemotherapeutic agents
Data are expressed as mean±SD. 
*P<.05 by Wilcoxon Signed Ranks test.
40.9% of patients (9/22) received four cycles of cyclophosphamide and
doxorubicin. 31.8% of patients (7/22) received four cycles of cyclophos-
phamide, doxorubicin, and paclitaxel. 27.2% of patients (6/22) received
six courses of CAF (cyclophosphamide, doxorubicin, 5-fluorouracil). Total
doses of cycloph-osphamide were significantly higher in the CAF regi-
men than in the AC or AC+ P regimens (P<.05).
AC, doxorubicin, cyclophosphamide; CAF, cyclophosphamide doxoru-
bicin, 5-Fluorouracil. 
Fig. 1. Overall gonadotropin levels before and after completion of
chemotherapy.
*Serum FSH levels 3 months after completion of chemotherapy
were significantly higher than those at 1 month or 6 months (P<
0.05); 
� Serum LH levels 3 months after completion of chemother-
apy were also significantly higher than those at 1 month or 6 months
(P<0.05).
*,� P<0.05 is considered significant by Kruskal-Wallis test with LSD.
m
I
U
/
m
L
20
10
0
FSH
LH
*
�
0 1234567
Months
Group A 
(range)
(n=18)
Group B 
(range)
(n=4) 
P
Age at diagnosis (yr) 31.1±0.4 28.5±0.3 0.46
BMI at diagnosis (kg/m
2) 20.8±1.6 21.0±0.5 0.62
Body surface area (m
2) 1.6±0.8 1.6±0.9 0.51
Breast cancer stage (TNM) 0.53
I7 1
IIa 2 2 
IIb 4 2
IIIa 4 0
Hormone receptor status
ER (+) 16 1  0.07
PR (+) 16 0 0.04*
Type of primary surgery 0.18
BCS 8 4 
MRM 9 0
TM 1 0
Chemotherapy regimen 0.17
AC 7 2
AC+Paclitaxel 8 0
CAF 3 2
Tamoxifen 0.02*
Medication (+) 16 1
Medication (-)2 3
Dose of Cyclophosphamidea 3678.3±0.1 4024.0±0.2 0.18
Gonadotrophin  at 3 months 
FSH 7.5±1.2 49.6±19.5 0.0075*
(1.3-16.5) (37.9-70.9)
LH 3.5±1.7 18.5±1.7 0.0075*
(0.6-5.9) (14-26.8)
E2 55.5±106.6 49.7±9.5 0.34
(10.0-468.1) (37.3-57.6)
Recovery of menstruations  1 0
at 3 month
Gonadotrophin at 6 months
FSH 6.9±2.75 8.9±8.0 0.98
(3.1-12.6) (3.7-18.3)
LH 4.1±2.1 5.5±4.6 1.0
(0.8-9.9) (1.6-12.3)
E2 121.3±177.3 61.2±18.6 1.0
(10.0-639) (42-85)
Recovery of menstruations  4 1
at 6 month
Table 3. Clinical profiles of patients with no increase in FSH or
LH 3 months after completion of chemotherapy (Group A) and
patients with increased FSH and LH 3 months after completion
of chemotherapy (Group B) 
Data are expressed as mean±SD.
P values by independent t-test or Fisher’s exact test.
Group A, Patients with no increase in FSH or LH 3 months after comple-
tion of chemotherapy; Group B, Patients with a significant increase in
FSH and LH 3 months after completion of chemotherapy.
Each values of gonadotropin (FSH/LH) were 38.4/14.0, 51.1/17.0, 37.9/
16.2 and 70.9/26.8 mIU/mL in Group B.
FSH, follicle stimulating hormone; BMI, body mass index; BCS, breast
consening surgery; MRM, modified radical mastectomy; TM, total mas-
tectomy; AC, doxorubicin, cyclophosphamide; CAF, cyclophosphamide
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six patients (27.2%) received six cycles of the cyclophospha-
mide, doxorubicin, and 5-fluorouracil (CAF) regimen. The
total doses of cyclophosphamide and of doxorubicin were
3741.3±15.7 mg and 381.3±12.4 mg, respectively. The
total dose of cyclophosphamide was significantly higher in
the CAF regimen than in the AC or AC+paclitaxel regimen
(4,512.5±103.2 vs. 3,598.6±93.8 or 3,443.0±117.2,
respectively; P<0.05) (Table 2).
Gonadotropin levels
Gonadotropin levels were evaluated at 1, 3, and 6 months
after the completion of chemotherapy. The mean time bet-
ween the last GnRHa injection and the first sampling was
44.0±19.2 (mean±SD, range: 28-55) days. Mean serum
FSH and LH levels were similar to baseline 6 months after
completion of chemotherapy (8.0±5.3 mIU/mL and 4.4±
2.7 mIU/mL, respectively); mean serum estradiol was 110.4
±l61.5 pg/mL. Overall, compared to baseline, gonadotropin
levels were significantly different 3 months after completion
of chemotherapy, while levels were in the normal range at 1
and 6 months (Fig. 1). In four patients, serum FSH 3 months
after completion was significantly higher than at 1 and 6
months (49.6±19.5 IU/mL) (P<0.05) (Table 3) and each
Fig. 2. Gonadotropin levels according to the chemotherapy regimen.
There was no significant correlation between serum gonadotropin levels and type of chemotherapy regimen (P>0.05).
P values by Kruskal-Wallis test with LSD.
AC, doxorubicin, cyclophosphamide; CAF, cyclophosphamide doxorubicin, 5-Fluorouracil. 
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AC
AC+Paclitaxel
CAF
Tamoxifen medication (range) 
(n=17)
No tamoxifen medication
(range) (n=5) 
P
Before chemotherapy
FSH 6.0±3.3 (2.1-11.3) 6.0±2.9 (2.3-9.8) NS
LH 5.5±2.3 (2.4-18.3) 4.9±2.5 (1.9-17.1) NS
Post-chemotherapy 
1 month after chemotherapy
FSH 5.1±3.2 (2.0-12.4) 4.8±3.1(2.0-6.7) NS
LH 2.1±1.4 (2.0-7.5) 2.90±1.5 (2.1-5.8) NS
E2 24.5±16.7 (10.0-78.0) 30.2±21.6 (10.0-56.3) NS
3 months after chemotherapy
FSH 20.8±11.0 (2.7-70.9) 35.3±19.4(3.6-51.1) <0. 05
LH 6.8±6.5 (3.0-15.8) 12.0±9.7 (3.7-19.9) NS
E2 55.4±96.0 (10.0-212.4) 61.3±90.4 (10.0-134.2) NS
Recovery of menses at 3 months 0 1
Menstruation (+) 0 (0%) 1 (20%) NS
Menstruation (-) 17 (100%) 4 (80%) NS
6 months after chemotherapy
FSH 7.6±3.8 (2.3-11.8) 4.9±3.2 (2.0-8.3) NS
LH 4.1±2.2 (3.3-8.2) 4.0±2.9 (2.1-9.0) NS
E2 102.6±123.8 (11.1-289.0) 138.1±172.0 (21.3-192.0) NS
Recovery of menses at 6 months 3 2
Table 4. Gonadotropin levels in patients with and without tamoxifen treatment after chemotherapy
Data are expressed as mean±SD.
P values by independent t-test or Fisher’s exact test.114 H.J. Park, Y.-A. Koo, Y.H. Im, et al.
values of gonadotropin (FSH/LH) in these patients were 38.4/
14.0, 51.1/17.0, 37.9/16.2 and 70.9/26.8 mIU/mL. How-
ever, despite this transient elevation, gonadotropin levels were
restored to the normal range 6 months after chemotherapy.
There were no significant differences between the two groups
except for the use of tamoxifen medication and a progesterone
receptor positive status (P<0.05) (Table 3). The total dose of
cyclophosphamide was the same between patients with ele-
vated FSH and patients with normal levels. In addition, there
were no statistically significant differences in gonadotropin
levels after completion of chemotherapy when different che-
motherapy regimens were compared (Fig. 2). The gonadotro-
pin levels were normal 6 months after the completion of che-
motherapy regardless of tamoxifen medication (Table 4). In
the patients with using tamoxifen, one showed elevated FSH
(51.1 mIU/mL) and her period was recovered at 13 months
after the completion of chemotherapy. 
Symptoms of ovarian failure
During the 6 months of follow-up, none of the patients
exhibited menopausal symptoms. Among those patients with
normal FSH levels at the 3-month follow-up, 61.1% (15/18)
experienced recovery of menstruation within 6 months, while
75% of patients (3/4) with elevated FSH at the 3-month fol-
low-up experienced menstrual cycle recovery. Symptom fol-
low-up of a mean duration of 35.6±1.7 months post-chemo-
therapy showed that 18 patients (81.8%) experienced men-
strual cycle recovery. One patient became pregnant within a
year of treatment completion and gave birth to a normal infant;
another woman became pregnant, but the pregnancy was ter-
minated. 
DISCUSSION
Advances in adjuvant chemotherapy for breast cancer have
led to improved long-term survival; however, chemothera-
peutic agents may cause profound long-term sequelae, includ-
ing damage to ovarian function in young patients (7-9). Ovar-
ian function is essential not only because it preserves fertili-
ty in cancer survivors, but also because it prevents the risk
of premature ovarian failure and the morbidities associated
with a hypoestrogenic state, including vasomotor symptoms,
osteoporosis, urogenital symptoms, and heart disease (3, 10,
11). It has been reported that approximately 64% of adult
women undergoing cancer therapy experience one or more
symptoms of ovarian failure (3). 
Several approaches have been taken to preserve ovarian func-
tion or fertility during chemotherapy including oophoropexy,
ovarian suppression, and cryopreservation of ovarian tissue,
oocytes, and embryos. None of these options have proven effi-
cacy except embryo cryopreservation, which has its own lim-
itations of requiring a current suitable sperm donor and a sur-
gicalprocedure. In contrast to these procedures, GnRHa injec-
tions are easily performed without surgery. Because dividing
cells are known to be more sensitive to cytotoxic drugs than
cells at rest, it has been suggested that inhibition of the pitu-
itary-gonadal axis could reduce the rate of oogenesis and there-
by render the germinal epithelium less susceptible to cytotox-
icity. Therefore, GnRHa, acting at an earlier stage of follic-
ular development, might prevent follicles from reaching the
chemotherapy-sensitive stage (4). An argument against the
efficacy of GnRHa is that, theoretically, GnRH analogues
preserve only follicles that have initiated growth, which con-
stitute <10% of the entire follicular pool in the ovary at any
given time. The ovarian reserve comprises 90% primordial
follicles that initiate follicle growth through an unknown
FSH-independent mechanism. In addition, primordial folli-
cles do not express FSH or GnRH receptors, which are uni-
formly present as early as the third or fourth granulosa layer
of preantral follicles. Nevertheless, current biological expla-
nations are not sufficient to explain the effects of GnRHa on
ovarian reserve. 
Despite its unknown mechanism, clinical studies have shown
that ovarian suppression by GnRHa can have a protective effect
on ovarian function during chemotherapy. However, infor-
mation regarding the effectiveness of this treatment in breast
cancer patients is limited, especially among women of repro-
ductive age, as most prior studies have evaluated women with
leukemia or Hodgkin’s lymphoma. Ataya et al. (12) showed
in rhesus monkeys that administration of GnRHa in paral-
lel with cyclophosphamide decreased the daily rate of follic-
ular decline and the total number of follicles lost significant-
ly, compared with cyclophosphamide alone. In addition, Blu-
menfeld et al. (13) reported that 96% of patients in their study
who received both chemotherapy and GnRHa resumed spon-
taneous ovulatory cycles, while only 35% of patients receiv-
ing chemotherapy alone did. In a study by Recchia et al. in
young women with breast cancer (5), all patients who received
GnRHa and adjuvant chemotherapy resumed normal menses.
The study enrolled 100 patients and the mean follow-up dura-
tion was 75 months. Although the total number of patients
in our current study is smaller and the follow-up duration
shorter, the median patient age is much younger than in the
study by Recchia et al. (31 yr vs. 43 yr, respectively). Our
study is unique in that it focuses on breast cancer patients in
their critical period of fertility (younger than the mid-30s).
By limiting enrollment to women of reproductive age, this
study evaluated the efficacy of GnRHa on protecting ovari-
an function during adjuvant chemotherapy in women whose
lives would be most affected by ovarian damage. 
We administered GnRHa 2 weeks prior to the initiation
of chemotherapy and confirmed ovarian suppression by serum
estradiol levels. A delay between GnRHa administration and
chemotherapy initiation is thought to provide better ovarian
protection than concurrent administration. Serial measure-
ment of gonadotropin levels demonstrated that they were nor-GnRH Agonist Therapy in Young Breast Cancer Patients 115
mal 6 months after chemotherapy. At the 6-month follow-up,
63.6% of patients experienced regular menstruation. Patients
were followed for a mean duration of 35.6±1.7 months and
81.8% (18/22) experienced recovery of menstruation. The
patients who did not resume menstruation (n=4) were all
taking tamoxifen during follow-up.
The mean total dose of cyclophosphamide in this study
was 3,706.10±83.60 mg, although there were significant
differences between regimens (CAF vs. AC vs. AC+paclitax-
el: 4,512.5±103.2 vs. 3,598.6±93.8 vs. 3,443.0±117.2,
respectively; P<0.05). The gonadotoxic dose of cyclophos-
phamide (single-drug regimen) is reported to be 5,200 mg,
9,300 mg, and 20,400 mg among women in their 40s, 30s,
and 20s, respectively (14). Although each dose of cyclophos-
phamide in our study was lower than the cumulative gona-
dotoxic dose before the onset of amenorrhea, gonadotoxicity
occurs at a lower dose when cyclophosphamide is used in com-
bination chemotherapy than with a single-drug regimen (15-
17). For example, the American Society of Clinical Oncolo-
gy reported that the risk of permanent amenorrhea among
women in their 30s receiving CAF, where the total dose of
cyclophosphamide is also lower than in the single drug reg-
imen, is intermediate (20-80%) (18). Because of synergistic
toxicity, the gonadotoxic effects of combination chemother-
apy cannot be interpreted based on the dosage of the chemoa-
gent alone.
At the 3-month follow-up, decreased ovarian reserve (FSH
>20 mIU/mL) was suspected in four patients. Their FSH lev-
els had returned to normal by the 6-month follow-up, and
three had resumed their normal menstrual cycles. The char-
acteristics of these four patients were compared with those
without an elevated FSH at the 3-month follow-up (Table 3).
The rate of decreased ovarian reserve was higher in patients
who did not receive tamoxifen (P<0.05). On this finding, it
could suggest that tamoxifen prevent the transient elevation
of hormone level. But, it needs more studies to conclude that
tamoxifen suppresses the elevation of gonadotropin level,
because the number of patients is small and the level of FSH
at 6 months did not show difference. A similar finding of ele-
vated FSH at the 3-month follow-up after completing che-
motherapy was reported in a study by Blumenfeld (19) on
monthly GnRHa injections in 44 women with lymphoma
receiving chemotherapy, aged 15 to 40 yr. Temporarily in-
creased FSH concentrations were detected in nearly one-third
of the patients who resumed normal ovarian function. The
mechanism of this phenomenon is unknown, but this find-
ing suggests that the gonadotropin level should be monitored
for at least 6 months after completing chemotherapy to thor-
oughly evaluate ovarian function. These preexisting markers
could not estimate ovarian reserve quantitatively and, in the
future, AMH, regarded as a novel marker of ovarian reserve,
may be useful for evaluating serial change of ovarian reserve. 
Despite the promising results of our study, we cannot con-
clude that ovarian suppression by GnRHa effectively preserves
ovarian function in young breast cancer patients receiving adju-
vant chemotherapy due to the lack of a control group. Fortu-
nately, several prospective randomized trials are presently ongo-
ing: the Zoladex Rescue of Ovarian Function (ZORO) study in
Germany, a multicenter study of Italian breast cancer pati-
ents, and a study by the Southwestern Oncology Group (SWOG-
S0230). If these trials demonstrate a beneficial effect  adotoxi-
city, clinical data on GnRHa treatment in young breast cancer
patients in Korea will need to be obtained in the near future.
Until then, our study will hopefully help clinicians to present
more informed options to young breast cancer patients seek-
ing methods to preserve their fertility. 
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